Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03173092 · ClinicalTrials.gov registry record · Phase 4
A Study of Ixazomib (NINLARO®) in Combination With Lenalidomide and Dexamethasone (IRD) for the Treatment of Participants With Multiple Myeloma (MM)
A Phase 4 study of Multiple Myeloma, sponsored by Takeda.
- Active
- Registry status
- Phase 4
- Development phase
- 141
- Enrollment target
- 20
- Study locations
NCT03173092: Active Phase 4 study of Multiple Myeloma, sponsored by Takeda.
NCT03173092 is a Phase 4 study of Multiple Myeloma that is active but no longer recruiting, run by Takeda. The registered enrollment target is 141 participants, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (74% lower). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03173092, a Phase 4 study of Multiple Myeloma, is active but no longer recruiting, sponsored by Takeda.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 4
- Development phase
- 141 participants
- Enrollment target
- 20
- Study locations
Study Summary
The main aim is to evaluate the effect of Ixazomib in combination with lenalidomide and dexamethasone on Multiple Myeloma disease progression at 2 years in participants who previously received a bortezomib-based induction regimen. The study will enroll approximately 160 participants, who are enrolled after completing 3 cycles of chemotherapy (Bortezomib-Based Induction Regimen). They are then treated with Ixazomib in addition to lenalidomide and dexamethasone.
Primary Outcome
PFS is defined as time from date of first administration of study drug regimen to date of first documentation of progressive disease (PD) based on local laboratory results and investigator's assessment using modified International Myeloma Working Group (IMWG) response criteria or death due to any cause, whichever occurs first.
Conditions Studied
Interventions
- DRUG Dexamethasone
- DRUG Lenalidomide
- DRUG Ixazomib
Study Locations (20)
California
- Los Angeles Cancer Network/(Formerly -Pacific Cancer Medical Center) - Anaheim
- Compassionate Care Research Group, Inc. - Fountain Valley
- Innovative Clinical Research - Santa Ana
Texas
- Texas Oncology- Presbyterian Cancer Center Dallas - Dallas
- Texas Oncology-San Antonio Northwest - San Antonio
- Millennium Physicians Association - Shenandoah
Maryland
- Saint Agnes Hospital - Baltimore
- American Oncology Partners of Maryland P.A - Bethesda
Missouri
- Central Care Cancer Center - Bolivar
- Kansas City Veterans Affairs Medical Center - Kansas City
Arizona
- Arizona Oncology Associates - Tucson
Colorado
- US Oncology Research - Colorado Springs
Florida
- Woodlands Medical Specialists- Pensacola - Pensacola
Georgia
- Winship Cancer Institute of Emory University - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 141 participants |
| Start Date | 2017-11-13 |
| Est. Completion | 2026-11-30 |
| Phase | Phase 4 |
What the registry record for NCT03173092 still lists
NCT03173092 is an interventional study that assigns participants to a tested intervention. The registered 141 participants enrollment target is mid-sized for trials with a published cap, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (74% lower).
The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 3 interventions - of which Dexamethasone is the first listed.
NCT03173092 names 20 study sites across 14 states, led by California, Texas, Maryland.
Frequently Asked Questions
What is clinical trial NCT03173092 about?
NCT03173092 is a clinical study titled "A Study of Ixazomib (NINLARO®) in Combination With Lenalidomide and Dexamethasone (IRD) for the Treatment of Participants With Multiple Myeloma (MM)". The main aim is to evaluate the effect of Ixazomib in combination with lenalidomide and dexamethasone on Multiple Myeloma disease progression at 2 years in participants who previously received a bortezomib-based induction regimen. The study will enroll approximately 160 participants, who are enroll...
What is the current status of trial NCT03173092?
This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 141 participants. The study started on 2017-11-13. Estimated completion is 2026-11-30.
What conditions does trial NCT03173092 study?
This clinical trial studies the following conditions: Multiple Myeloma.
What interventions are being tested in trial NCT03173092?
The interventions under investigation include: Dexamethasone (DRUG), Lenalidomide (DRUG), Ixazomib (DRUG).
Who is sponsoring clinical trial NCT03173092?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03173092 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03173092's enrollment target sits among peer trials
141 139th of 438 higher than 300 of 438 other Multiple Myeloma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Multiple Myeloma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)
RECRUITING · Phase 4
-
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
RECRUITING · Phase 4
-
Evaluating Premedication Regimens (Methylprednisolone vs Dexamethasone-based) for the Prevention of Systemic and Injection Site Reactions to Motixafortide in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization, PARADE Trial
RECRUITING · Phase 4
-
Lenalidomide and Dexamethasone With/Without Stem Cell Transplant in Patients With Multiple Myeloma
COMPLETED · Phase 4
-
Zoledronic Acid Treatment (Every 4 or 12 Weeks) to Prevent Skeletal Complications in Advanced Multiple Myeloma Participants
COMPLETED · Phase 4
-
Evaluation of VELCADE Given as Retreatment to Multiple Myeloma Patients for Efficacy, Safety and Tolerability
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03042962 · 141 participants
Brain Networks in Dystonia
- NCT04378439 · 141 participants · NA
Appalachian Partnership to Reduce Disparities (Aim 2)
- NCT04775485 · 141 participants · Phase 2
A Study to Evaluate Tovorafenib in Pediatric and Young Adult Participants With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors
- NCT05040360 · 141 participants · Phase 2
Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI